Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban

Thrombosis and Haemostasis

Volumn 113, Issue 1, 2015, Pages 77-84

  Gosselin, Robert C ^a   Adcock, Dorothy ^b   Hawes, Emily M ^c   Francart, Suzanne J ^c   Grant, Russell P ^b   Moll, Stephan ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dabigatran; Drug calibrators; Reagent sensitivity; Rivaroxaban

Indexed keywords

DABIGATRAN; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; BLOOD CLOTTING TIME; CALIBRATION; DRUG EFFECT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; ANALOGS AND DERIVATIVES; BLOOD CLOTTING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG LABELING; EVALUATION STUDY; HUMAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; REPRODUCIBILITY; STANDARD; STANDARDS; UNITED STATES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; CALIBRATION; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LABELING; HUMANS; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; THIOPHENES; UNITED STATES;

EID: 84922381111     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-04-0361     Document Type: Article

References (18)

1. van Ryn J, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-11127.
2. Dager WE, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 2012; 46: 1627-1636.
3. Mani H, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109: 127-136.
4. Hawes EM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-1502.
5. Francart SJ, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014; 111: 1133-1140.
6. Gosselin RC, et al. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 2013; 47: 1635-1640.
7. Douxfils J, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
8. Mani H, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108: 191-198.
9. Samama MM, et al.; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
10. Huisman MV, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
11. Turpie AG, et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-886.
12. Baglin T, et al. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159: 427-429.
13. Baglin T, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760.
14. Douxfils J, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
15. Samama MM, et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
16. Gosselin RC, Dwyre DM. Determining the effect of freezing on coagulation testing: comparison of results between fresh and once frozen-thawed plasma. Blood Coag Fibrinol 2014; Epub ahead of print.
17. Gosselin R, et al. Effect of telavancin (Vibativ) on routine coagulation test results. Am J Clin Pathol 2011; 136: 848-854.
18. van den Besselaar AM, et al. Phosphatidylglycerol and daptomycin synergistically inhibit tissue factor-inducedcoagulation in the prothrombin time test.,J Thromb Haemost 2010; 8: 1429-1430.